Tranquility Partners LLC Has $1.16 Million Position in Zoetis Inc. $ZTS

Tranquility Partners LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 2.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,436 shares of the company’s stock after selling 199 shares during the period. Tranquility Partners LLC’s holdings in Zoetis were worth $1,160,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the first quarter valued at $25,000. 1248 Management LLC acquired a new position in shares of Zoetis in the first quarter valued at $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the first quarter valued at about $29,000. REAP Financial Group LLC boosted its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC boosted its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 1.6%

ZTS opened at $141.05 on Friday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a 50-day simple moving average of $149.24 and a 200 day simple moving average of $154.41. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $62.51 billion, a price-to-earnings ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 earnings per share. Zoetis’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio is currently 34.42%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZTS. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Argus reissued a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.